|
|
|
|
|
|
|
|
|
|||||||
September 2010 – Minton Named Naprogenix CEO - Naprogenix, Inc., a drug discovery and plant biotechnology company based on University of Kentucky and proprietary intellectual property, announced today that it has appointed Terry Minton to be its CEO, effective immediately. Minton, a Louisville resident with a wealth of experience in the healthcare and biotechnology industries, is best known for his having launched the cancer therapeutics company Aptamera with Dr. Donald M. Miller, Director of the James Graham Brown Cancer Center. Amidst the economic disruption wrought by the events of September 11, 2001, Minton raised several million dollars in angel and venture funding and positioned the company for its acquisition by the British pharmaceutical company Antisoma PLC. Minton has held CEO and other leadership positions with various companies in the healthcare technology and biotechnology sector. Additionally, he spearheaded the development of high-value intellectual properties at the Innovation Center for a Kentucky-based Fortune 100 health benefits provider. “Terry Minton is the perfect fit to lead Naprogenix – an experienced biotech CEO who has raised millions in equity capital and formed alliances with global companies capable of taking products created by the Naprogenix technology platform into worldwide distribution,” said John M. Littleton, M.D., PhD., Chief Scientific Officer and Co-Founder of Naprogenix. “Not only does Terry Minton understand this space, he has a consistent track record of delivering in fundraising, product development and intellectual property licensing and other monetization activities,” added Littleton, who had been serving as interim CEO until a nationwide search for a replacement led Naprogenix to Minton. Naprogenix is the recipient of over $6 million in National Institutes of Health (NIH) Small Business Innovation Research (SBIR) and Small Business Technology Transfer Research (STTR) funding, as well as support from the Kentucky Science and Technology Corporation, and is the exclusive licensee of patented technology owned by the University of Kentucky Research Foundation, Inc. Naprogenix’s technology harnesses the power of plant metabolism by subjecting native and engineered plant extracts to high-throughput pharmacological screening to discover novel, patentable structures and activities useful for the treatment of neurodegenerative diseases, cancer, age-related macular degeneration, and other chronic diseases. Certain of the natural products are also useful as all-natural pesticides. Minton will serve as President/CEO and Chairman of the Board of Directors of Naprogenix and is expected to focus initial efforts on accelerating product development along with consummation of strategic alliances with global healthcare, nutritional and personal care products companies.
June 2007 – National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded Phase II STTR Grant on “Transgenic plant cells as a source of hepatoprotective drugs”
May 2007 – Deane L. Falcone, PhD (Chief Molecular Science) represented Naprogenix at BIO 2007 conference in Boston, MA. Dr. Falcone presented a poster on “A novel integrated strategy for plant drug discovery based on high throughput pharmacological screening (HTPS) and plant genomics” Click to see poster or abstract
Fall 2006 – Naprogenix was featured in the University of Kentucky College of Agriculture “the Magazine” article titled “Biotechnology – Moving Beyond the Lab”. Click the links below to view the article as either pdf or html: August 2006 - National Cancer Institute (NCI) awarded Phase I STTR Grant on “Novel estrogen receptor ligands from plant genomics”
September 2004 – National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded Phase I STTR Grant on “Potential anti-relapse drugs: a plant genomics approach” June 2004 – National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded Phase I STTR Grant on “Application of plant genomics to alcoholic brain damage” September 2003 – National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded Phase I STTR Grant on “Transgenic plant cells as a source of hepatoprotective drugs” 2003 – Naprogenix obtains the exclusive license agreement with the University of Kentucky on patented NPG technology. |
|||||||
